Showing 120 of 120on this page. Filters & sort apply to loaded results; URL updates for sharing.120 of 120 on this page
Genprex to Participate at BIO International Convention 2026
Genprex Reqorsa lung cancer data at AACR 2026 | GNPX Stock News
GNPX Stock Price | Genprex Inc. Stock Quote (U.S.: Nasdaq) | MarketWatch
Genprex updates diabetes gene therapy collab, spins out new company ...
Genprex Appoints Jan Stevens, RN, as Vice President of Clinical ...
Genprex Granted Key Patents in Japan and Europe for Cancer Therapy
Genprex Receives Australian Patent for Cancer Therapy Combination
Genprex to Present and Participate at Upcoming September Investor and ...
Genprex is Defining a New Immunogene Therapy that Could Change the ...
Genprex (GNPX) Pops As Reqorsa Data Impresses At AACR 2026
Genprex unveils groundbreaking data from primate study on its novel ...
Genprex Signs Sponsored Research Agreement to Study Biomarkers that May ...
Genprex Oncoprex screenshot
Genprex to Participate in March Investor and Industry Conferences – Genprex
Genprex to Receive Inaugural “License of the Year” Award from ...
Genprex Signs Sponsored Research Agreement with the University of ...
Genprex Receives Notice of Allowance for Multiple Patents for Reqorsa ...
Genprex Announces Centralized Institutional Review Board Approval for ...
Genprex to Participate in Panel at Life Sciences Summit on November 17 ...
Genprex Collaborators Present Positive Preclinical Data on Reqorsa ...
Genprex Announces Sponsored Research Agreement with The University of ...
Genprex Announces U.S. Patent for Reqorsa® Gene Therapy in Combination ...
Genprex Provides Update on Development of its Oncoprex Immunogene ...
Genprex Collaborators Report Positive Preclinical Data on the Use of ...
Genprex Announces the Passing of its Co-Founder and Chief Executive ...
Genprex Receives U.S. FDA Fast Track Designation for REQORSA ...
Genprex Strengthens Diabetes Gene Therapy Program with License of ...
Genprex Collaborators to Present Positive Preclinical Data on Diabetes ...
Genprex Collaborators Report Positive Preclinical Data With NPRL2 Gene ...
Genprex Featured in CEO/CFO Magazine Discussing Novel Gene Therapies ...
Genprex to Participate at BIO Europe Spring 2026 – Genprex
Genprex Unveils New Video Featuring Chief Medical Officer Discussing ...
Genprex to Showcase Gene Therapies for Cancer and Diabetes at BIO 2025 ...
Genprex Appoints Suzanne Thornton-Jones as Senior Vice President ...
Genprex Collaborators to Present Positive Preclinical Data on Reqorsa ...
Genprex Receives Patent Allowances for Reqorsa Combination Therapies ...
Genprex to Present Trial Design of Acclaim-3 Clinical Trial Evaluating ...
Genprex (GNPX.O) Sees 15% Intraday Spike—What's Behind the Surge?
Genprex to Participate at the 43rd Annual J.P. Morgan Healthcare ...
Genprex Granted Patent in Singapore for Gene Therapy to Treat Cancers ...
Genprex Collaborators Present Positive Preclinical Data on the Use of ...
Genprex to Host a Virtual Key Opinion Leader Event on “Bringing Gene ...
Genprex (GNPX) Stock Soars on Lung Cancer Gene Therapy Data - Parameter
Independent Researchers Find That TUSC2, the Gene Delivered by Genprex ...
The results are in, Genprex (NASDAQ: GNPX) announces positive ...
Genprex (NASDAQ:GNPX) Stock Skyrockets 40% on Lung Cancer Gene Therapy ...
Genprex (GNPX.O) Surges 20% — What’s Driving This Unusual Move?
Genprex Strengthens Scientific Advisory Board with Appointment of Lead ...
Genprex (GNPX) Surges 26.8% on Preclinical Breakthroughs and ...
Genprex Announces Formation of Clinical Advisory Board – Genprex
Genprex Expands Gene Therapy Oncology Pipeline to Include Small Cell ...
Genprex Announces European Patent Office’s Intent to Grant a Patent for ...
Genprex Adds Clinical Trial Site for Acclaim-1 and Acclaim-3 Lung ...
Genprex Inc.: Navigating the Financial Waters Amidst Market Volatility
Genprex Announces $1.26 Million Registered Direct Offering – Genprex
Genprex Collaborators to Present Positive Preclinical Data on the Use ...
Genprex Announces Registered Direct Offering of up to $8.2 Million ...
Genprex to Present at the 2021 Virtual Cell & Gene Meeting on the ...
Genprex Announces Groundbreaking Data from Non-Human Primate Study ...
Genprex (GNPX) Surges 20% on Technical Signal and Patent Hype – What’s ...
Genprex Collaborators Find NPRL2 Gene Therapy Using Oncoprex® Delivery ...
Genprex Granted FDA Orphan Drug Designation (ODD) for REQORSA ...
Genprex Announces Preclinical Data for TUSC2 Immunogene Therapy in Non ...
Genprex Collaborators Report Positive Preclinical Data for REQORSA ...
Genprex Plummets 21% on $10M Capital Raise Amid Preclinical Hype
Genprex Announces 1-for-40 Reverse Stock Split Effective February 2 ...
Genprex to Accelerate Opening of Acclaim-1 Clinical Trial Sites for ...
Genprex is Pioneering the Use of Non-Viral Vectors in Gene Therapy ...
Genprex to Participate at BIO Europe Spring 2025 – Genprex
Genprex to Participate in CEO Roadshow Webinar Series – Genprex
Genprex Announces First Patient Dosed in Phase 2 Expansion Portion of ...
News – Genprex
Genprex Begins Next Phase of Drug Branding Program – Genprex
Genprex Announces $7.5 Million Registered Direct Offering Priced At-the ...
Genprex Signs License Deal With University Of Michigan For Lung Cancer ...
Genprex Stock Quote GNPX - Stock Price, News, Charts, Message Board, Trades
Genprex Collaborators Publish Positive Preclinical Data with NPRL2 Gene ...
Genprex Stock Sees Surprising Climb: Are New Trials Boosting Investor ...
Genprex (GNPX) Price Target Increased by 45.45% to 8.16 | Nasdaq
About Us – Genprex
Genprex, Inc. on LinkedIn: Genprex (NASDAQ: GNPX): focused on ...
Genprex to Participate in a Monthly CEO Roadshow Webinar Series ...
Genprex, Inc. on LinkedIn: Genprex had so much fun participating in the ...
Genprex Shares Seek Catalysts Amid Clinical Trial Focus
Genprex and University of Pittsburgh sign new agreement to study GPX ...
Genprex Announces U.S. Patent for REQORSA™ Immunogene Therapy in ...
Genprex (GNPX) Surges 47% on Intraday Rally: What’s Fueling the Momentum?
Genprex expanding trial research and portfolio for cancer and diabetic ...
Genprex cancer gene therapy paired with AZ, Merck lung cancer drugs ...
Genprex Wins FDA Fast Track Status for its Oncoprex Therapy in ...
Austin-based Genprex shares promising gene therapy developments for ...
How Genprex Differs From “Traditional” Gene Therapy Approaches – Genprex
Data from Genprex’s Acclaim-1 Phase 1 Gene Therapy Clinical Trial ...
Genprex, Inc. Prices $17,500,000 Common Stock Offering Priced At-The ...
Genprex, Inc. Announces Closing of $8 Million At-The-Market Common ...
Genprex’s Non-Viral Delivery System Once Again Ahead of Recent Industry ...
Genprex’s Novel Immunogene Therapy in Lung Cancer Highlighted in Key ...
New Research on Genprex, Inc. (GNPX-NASDAQ)
Gene Therapy Stock Genprex, Inc. (NASDAQ: GNPX) Makes Nasdaq Top ...
Genprex, Inc. on LinkedIn: #sclc
Planned Spin-Out to Focus on Gene Therapy for Type 1 and 2 Diabetes in ...
Genprex, Inc. Announces $12 Million Registered Direct Offering Priced ...
Genprex, Inc. on LinkedIn: Genprex's Executive Vice President, General ...
Genprex, Inc. on LinkedIn: #bioeuropespring #cancer #diabetes
Genprex, Inc. on LinkedIn: #bioeurope #cancer #diabetes
Genprex’s Reqorsa Gene Therapy - Mesothelioma Gene Treatment
Genprex, Inc. on LinkedIn: #genetherapy #diabetes #attd2023
Genprex, Inc. | LinkedIn
March 23 2023
IBN Announces Latest Episode of The Bell2Bell Podcast featuring CEO ...
Genprex, Inc. (NASD:GNPX) Seasonal Chart | Equity Clock
Genprex, Inc. on LinkedIn: #cancerimmunotherapymonth
